Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
Holding VYGR?
Track your performance easily
VYGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.99 - $10.66
Previous CloseN/A
Volume91.62K
Average Volume (3M)383.75K
Market Cap
$276.41M
Enterprise Value$38.42M
Total Cash (Recent Filing)$174.42M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)7.0
Beta1.08
Next Earnings
Mar 11, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding54,625,587
10 Day Avg. Volume375,307
30 Day Avg. Volume383,751
Standard Deviation0.22
R-Squared0.05
Alpha-0.00577
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.69
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue0.23
Enterprise Value/Gross Profit0.15
Enterprise Value/Ebitda1.49
Forecast
1Y Price Target
$16.38Price Target Upside223.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Voyager Therapeutics News
PremiumCompany Announcements
Voyager Therapeutics Reports Strong Q3 2024 Progress
Bulls Say, Bears Say
Bulls Say
Financial StrengthVoyager has generated ~$524M in upfront payments from partnerships and out-licensing deals, with >$8B in potential milestone payments.
Innovative TechnologyVoyager's proprietary TRACER platform for next-generation AAV capsids has established Voyager as a leader in the CNS gene therapy space and as a preferred BD partner for pharma.
Promising Alzheimer's TreatmentManagement highlighted the potential for its lead program VY7523, an anti-tau monoclonal antibody in Phase 1 development, to emerge as a highly differentiated treatment for Alzheimer's disease based on promising in vivo preclinical data.
Bears Say
Collaboration TerminationRoche terminated collaboration on the asset – reading across negatively to sentiment on VYGR’s lead tau-antibody VY7523.
Preclinical Data And Antibody EfficacyVYGR presented preclinical data demonstrating that two N-terminal directed mAbs previously failed to significantly reduce tau spread in the model.
Target Population And Clinical RelevanceThe lack of clarity on the adequate target population for the approach and the clinical relevance of the magnitude of changes observed continues to highlight a complicated road ahead for this modality.
---
Ownership Overview
2.40% Insiders
13.29% Mutual Funds
28.59% Other Institutional Investors
45.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $4.99 and its highest was $10.66 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $276.41M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 49 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.445 by $0.285.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 54,625,587 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.445. Following the earnings report the stock price went down -2.05%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Among the largest hedge funds holding Voyager Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Voyager Therapeutics’s shares valued at 13M.
---
Voyager Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.38 (223.08% Upside)
$16.38 (223.08% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 352.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.54%
12-Months-Change
Fundamentals
Return on Equity
10.22%
Trailing 12-Months
Asset Growth
44.59%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
---
VYGR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant advancements in partnerships, financial stability, and Alzheimer's research. However, challenges in clinical trial outcomes and patient selection were noted. Overall, there is optimism about the potential of their pipeline and strategic partnerships.Read More>---
VYGR Stock 12 Month Forecast
Average Price Target
$16.38
▲(223.08% Upside)
Technical Analysis
Adverum Biotechnologies
―
Clearside Biomedical
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Meiragtx Holdings
―
Allogene Therapeutics
―
Best Analysts Covering VYGR
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+1.29%
reiterated a buy rating 2 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +1.29% per trade.
---